Medicamen Biotech enterprise value

Share price at each year-end

Tap a line for its trend	Currentlast 12M	FY26Mar 2026	FY25Mar 2025	FY24Mar 2024	FY23Mar 2023	FY22 and earlierAlpha Plus


345	—	—	—	—	FY22 and earlierEvery year the company has filed comes with Alpha Plus.
31.3	31.3	3.8	14.8	20.8
47.8	47.8	33.3	30.8	24.2
361	—	—	—	—
16.5	16.5	29.5	16.0	3.4
₹266.43	—	—	—	—

323	323	246	231	218
14.8%	14.8%	13.5%	13.3%	11.1%
0.13×	—	—	—	—

1.78×	—	—	—	—
18.73×	—	—	—	—
29.88×	—	—	—	—
203	198	163	179	141
19.3	19.6	13.9	22.2	23.9
12.1	12.4	6.8	15.1	17.5
—	−33.2	−7.2	−0.4	−6.3
−38.0	−38.0	−9.3	−6.7	−12.9
—	−38.6	−10.3	−7.9	−13.3
—	4.8	2.1	6.3	6.6

Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

alphave

MEDICAMEQ₹254.25

Medicamen Biotech Limited

· Pharma & Health

₹ CrorePeersMEDICO AAREYDRUGS NECLIFE HALEOSLABS ALBERTDAVD NATCAPSUQ VALIANTLAB BALPHARMAMcap ₹345 Cr

HighlightsEnterprise Value Multiples Per ShareAnnuals · FY-end closes

In ₹ Crore except Per Share 12 Months Ending	FY23 31/03/2023	FY24 31/03/2024	FY25 31/03/2025	FY26 31/03/2026	Current/LTM TTM · last close
Market Capitalization	—	—	—	—	344.8
- Cash, Equiv & ST Investments	20.8	14.8	3.8	31.3	31.3
+ Total Debt	24.2	30.8	33.3	47.8	47.8
Enterprise Value	—	—	—	—	361.4
Net Debt (memo)	3.4	16.0	29.5	16.5	16.5
EV per Share	—	—	—	—	266.43

Total Capital	217.6	231.3	246.0	323.3	323.3
Total Debt/Total Capital	11.11	13.32	13.52	14.78	14.78
Total Debt/EV	—	—	—	—	0.13

EV/Sales	—	—	—	—	1.78
EV/EBITDA	—	—	—	—	18.73
EV/EBIT	—	—	—	—	29.88
Reference Items — Trailing FY Values
Sales	140.9	179.3	162.5	197.8	202.6
EBITDA	23.9	22.2	13.9	19.6	19.3
EBIT	17.5	15.1	6.8	12.4	12.1
Operating Cash Flow	-6.3	-0.4	-7.2	-33.2	—
Free Cash Flow	-12.9	-6.7	-9.3	-38.0	-38.0
FCFF (free cash flow to the firm)	-13.3	-7.9	-10.3	-38.6	—
Capital Expenditure	6.6	6.3	2.1	4.8	—

Market Cap/EV/multiples pair each (split/bonus-adjusted) FY-end close with the latest filed share count; Current column uses the last close. Market Capitalization is a market-level figure — identical across Consolidated/Standalone (the accounting rows below differ). No consensus estimates → no Est columns. Click any row to chart it.

« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave

Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.